JP2023508173A5 - - Google Patents
Info
- Publication number
- JP2023508173A5 JP2023508173A5 JP2022539175A JP2022539175A JP2023508173A5 JP 2023508173 A5 JP2023508173 A5 JP 2023508173A5 JP 2022539175 A JP2022539175 A JP 2022539175A JP 2022539175 A JP2022539175 A JP 2022539175A JP 2023508173 A5 JP2023508173 A5 JP 2023508173A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/127903 | 2019-12-24 | ||
| CN2019127903 | 2019-12-24 | ||
| PCT/CN2020/138591 WO2021129656A1 (en) | 2019-12-24 | 2020-12-23 | Novel anti-fgfr2b antibodies |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023508173A JP2023508173A (ja) | 2023-03-01 |
| JPWO2021129656A5 JPWO2021129656A5 (https=) | 2024-01-05 |
| JP2023508173A5 true JP2023508173A5 (https=) | 2024-01-05 |
| JP7686000B2 JP7686000B2 (ja) | 2025-05-30 |
Family
ID=76573701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539175A Active JP7686000B2 (ja) | 2019-12-24 | 2020-12-23 | 新規抗ＦＧＦＲ２ｂ抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230052256A1 (https=) |
| EP (1) | EP4081539A4 (https=) |
| JP (1) | JP7686000B2 (https=) |
| KR (1) | KR20220119143A (https=) |
| CN (1) | CN114901687A (https=) |
| AR (1) | AR120884A1 (https=) |
| AU (1) | AU2020410863A1 (https=) |
| CA (1) | CA3160811A1 (https=) |
| MX (1) | MX2022007960A (https=) |
| TW (1) | TWI861325B (https=) |
| WO (1) | WO2021129656A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023243773A1 (en) * | 2022-03-28 | 2024-10-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Novel anti-fgfr2 antibodies. |
| CN117917435A (zh) * | 2022-10-21 | 2024-04-23 | 北京天广实生物技术股份有限公司 | 结合fgfr2b的抗体及其用途 |
| WO2024199362A1 (en) * | 2023-03-31 | 2024-10-03 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Novel anti-FGFR2 antibodies |
| CN118994393A (zh) * | 2023-05-19 | 2024-11-22 | 广东东阳光药业股份有限公司 | 一种抗fgfr2抗体及其应用 |
| WO2025146131A1 (en) * | 2024-01-05 | 2025-07-10 | Beigene, Ltd. | ANTI-FGFR2b ANTIBODIES, CONJUGATES AND METHODS OF USE |
| CN121319178A (zh) * | 2024-07-02 | 2026-01-13 | 安博泰克药业有限公司 | 特异性结合FGFR2b的抗体及其与药物的缀合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1717248A1 (en) * | 1997-06-04 | 2006-11-02 | Oxford Biomedica (UK) Limited | Tumor targeted vector |
| CA2518371A1 (en) * | 2003-03-14 | 2004-09-30 | Wyeth | Antibodies against human il-21 receptor and uses therefor |
| AU2003271174A1 (en) * | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| WO2005037235A2 (en) * | 2003-10-16 | 2005-04-28 | Imclone Systems Incorporated | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| CA2572289A1 (en) * | 2004-06-30 | 2006-08-17 | Centocor, Inc. | Anti-mcp-1 antibodies, compositions, methods and uses |
| EP2046384A4 (en) * | 2006-06-15 | 2009-12-02 | Fibron Ltd | ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME |
| PL2365828T3 (pl) * | 2008-11-07 | 2015-04-30 | Galaxy Biotech Llc | Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów |
| RU2014109038A (ru) * | 2011-08-23 | 2015-09-27 | Рош Гликарт Аг | Антитела к хондроитинсульфат протеогликану меланомы |
| AR088941A1 (es) * | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| AU2012351685A1 (en) * | 2011-12-14 | 2014-07-03 | Seattle Genetics, Inc. | FGFR antibody drug conjugates (ADCs) and the use thereof |
| PH12021552742A1 (en) * | 2013-08-01 | 2022-05-23 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
| CA2961439A1 (en) * | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| US20170145103A1 (en) * | 2015-11-23 | 2017-05-25 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
| DK3380522T5 (da) * | 2015-11-25 | 2024-09-30 | Visterra Inc | Antistofmolekyler til april og anvendelser deraf |
| WO2018095932A1 (en) * | 2016-11-22 | 2018-05-31 | Merck Patent Gmbh | Monoclonal antibody directed to fgfr1 |
| JP7265476B2 (ja) * | 2016-11-22 | 2023-04-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｆｇｆｒ１を対象とするモノクローナル抗体 |
| CA3160810A1 (en) * | 2019-12-24 | 2021-07-01 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| MX2022007961A (es) * | 2019-12-24 | 2022-07-12 | Dizal Jiangsu Pharmaceutical Co Ltd | Nuevos anticuerpos anti-fgfr2b. |
-
2020
- 2020-12-23 US US17/788,730 patent/US20230052256A1/en active Pending
- 2020-12-23 CN CN202080089840.3A patent/CN114901687A/zh active Pending
- 2020-12-23 MX MX2022007960A patent/MX2022007960A/es unknown
- 2020-12-23 KR KR1020227025531A patent/KR20220119143A/ko active Pending
- 2020-12-23 CA CA3160811A patent/CA3160811A1/en active Pending
- 2020-12-23 WO PCT/CN2020/138591 patent/WO2021129656A1/en not_active Ceased
- 2020-12-23 AR ARP200103629A patent/AR120884A1/es unknown
- 2020-12-23 AU AU2020410863A patent/AU2020410863A1/en active Pending
- 2020-12-23 JP JP2022539175A patent/JP7686000B2/ja active Active
- 2020-12-23 EP EP20907461.6A patent/EP4081539A4/en active Pending
- 2020-12-24 TW TW109145974A patent/TWI861325B/zh active